<b>A</b>		·			$\mathcal{L}(\mathcal{L}_{1})$	Angal Ma		39385									
		•					110/539	385									
ORM PTO-1449 NFORMATION DISCLOSURE STATEMENT					SERIAL NO. FILING DATE APPLICANT		June 16, 2005  Bamford et al.  1624										
														GROUP		Colema	<u> </u>
														EXAMINER			
						DOCKET NO.	P331390	5W									
			U.S. I	PATENT D	OCUMENTS			Filing Date									
xaminer		Patent	Issue Date		Name	Class	Subclass	If Appropriate									
Initials		Number		<u> </u>		540	594										
7B.C./	i.	4,210,749	7/1/1980	Shetty			320.1										
<del>/B.C./  </del>		5,364,791	11/15/1994	Vegeto e		435		<del> </del>									
<del>/B.C./</del>	$\frac{2}{3}$	5,874,534	2/23/1999	Vegeto e		530	350	<del> </del>									
/B.C./	4.	5,935,934	10/10/1999	Vegeto e		514	44	<del> </del>									
7B.C./	5.	2004/0053826	3/18/2004	Matsum		514	012	<del> </del>									
/B.C./		2004/0063699	4/1/2004	Tarui et	al.	514	227.8	L									
/D.U./	6.	2004/0003099	FORFIC		T DOCUMEN	TS		T									
		Document	Publication Date		Country	Class	Subclass	Translation Yes   No									
<del>/0 / -  </del>		Number	1/10/2002	PCT				abstract only									
/B.C./ /B.C./	7.	WO 02/02530 - WO 01/03680 .	1/18/2001	PCT				<b></b>									
	8.		11/22/2001	PCT				<u> </u>									
/B.C./	9,	WO 01/87834		PCT													
/B.C./	10.	WO 04/026305 -	4/1/2004	PCT				abstract only									
/B.C./	11.	WO 02/14513 ·	2/21/2002														
/B.C./	12.	WO 03/90751	11/6/2003	PCT			<del> </del>										
/B.C./	13.	WO 00/21951 '	4/20/2000	PCT			+										
/B.C./	14.	WO 02/040471	5/23/2002	PCT			<del></del>	abstract only									
/B.C./	15.	WO 02/15934	2/28/2002	PCT			<del> </del>	abstract only									
/B.C./	16.	WO 99/55677	11/4/1999	PCT													
/B.C./	17.	1 331 010	7/30/2003	EP				1 -441:									
/B.C./	18.		7/23/1981	DE				abstract only									
<del>/B.C./</del>	19.	2171879	9/28/1973	FR				abstract only									
<del>/B.C./</del>			3/22/1972	GB				<del></del>									
/B.C./	20:		8/21/2001	JР				abstract only									
	21.	4 000 100	2/12/2003	EP													
7B.C.7	22			I'm Andba	or Title Journa	I-Date, Page Nu	mber, Etc.)										
/B.C./		AUSTIN et al., No	vel 2,3,4,5-Tetr	ahydro-l <i>H</i>	-3-benzazepines	etters 10:2553-2	555 (2000).										
	<del></del> +	Dopamine D3 Reco	etics of the Am	eous Perio	date Oxidation o	f Aliphatic Disul	fides with Thic	oethers, J. Org.									
/B.C./		Dopamine D <sub>3</sub> Receptor, Bioorganic & Medicinal Chemistry Estate Period States and Provided States and Prov															
/B.C./		scopolamine-induced amnesia," Behavirural Brain Res. 104:147-155 (1999).  LEURS et al., "Therapeutic potential of histamine H <sub>3</sub> receptor agonists and antagonists," TiPS 19:177-183															
/B.C./		(May 1998).  LOVENBERG et al., "Cloning and Funcational Expression of the Human Histamine H <sub>3</sub> Receptor," Molecular															
/B.C./		Pharmacology 55:1101-1107 (1999).															
/B.C./	28.	carboxylic Acids as a Novel Class of Endothelin Receptor Antagonists, Bloodgaine & Medical Control of the Contr															
/B.C./	29.	Letters 12:3041-3045 (2002).  ONODERA and WATANABE, "Histamine H <sub>3</sub> Antagonists as Potential Therapeutics in the CNS," ed Leurs and Timmerman, pp255-267, Elsevier Science B.V. (1998).  SCHLICKER et al., "Modulation of neurotransmitter release via histamine H <sub>3</sub> heteroreceptors," Fundam Clin															
/B.C./	30.																
/B.C./	31.	Pharmacol 8:128- RILEY et al., The Biochemical Jour	Reaction of Pronal 131(4):625-	otein Amin 635 ( <u>1973</u> )	o Groups with M	temyi 5-10dopyn	TE CONSIDE	RED 03/21/2008									
EXAMINE	·R	/Brenda Col				DA DA	ים ביונטאוטט פיי	~~03/21/2008									

<sup>\*\*</sup> structures only